Table 3.

Drugs targeting protein phosphatases involved in inflammation in clinical trials

Compound	Target	Conditions	Phase	Status	Combination Therapy	NCT Number
TNO155	SHP2	NSCLC Esophageal SCC, Head/Neck SCC, Melanoma	Phase 1	Recruiting	Nazartinib	NCT03114319
		NSCLC Esophageal SCC, Head/Neck SCC, Melanoma	Phase 1	Recruiting	Spartalizumab or Ribociclib	NCT04000529
		Gastrointestinal Stromal Tumors
		Colorectal Cancer
		Advanced solid tumors with KRASG12C mutation	Phase 1/2	Recruiting	JDQ443	NCT04699188
		Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease	Phase 1/2	Recruiting	MRTX849 or Dabrafenib, LTT462	NCT04330664
		BRAFV600E Colorectal Cancer	Phase 1	Recruiting	Trametinib,	NCT04294160
BBP-398	SHP2	Advanced solid tumor	Phase 1	Recruiting	None	NCT04528836
JAB-3068	SHP2	NSCLC,	Phase1/2	Recruiting	None	NCT03565003,
		Head and Neck Cancer, Metastatic Solid Tumors				NCT03518554
RMC-4630	SHP2	Pancreatic Cancer,	Phase	Recruiting	Sotorasib, LY3214996	NCT05054725
		Colorectal Cancer, NSCLC	1/1b/2	or Active	Cobimetinib	NCT03634982
		KRAS mutation related tumors			Osimertinib	NCT03989115
						NCT04916236
RLY-1971	SHP2	Solid Tumor	Phase 1	Recruiting	None	NCT04252339
JAB-3312	SHP2	NSCLC, Colorectal Cancer, Pancreatic Ductal Carcinoma, Esophageal SCC, Head and Neck SCC, Breast Cancer, Other Solid Tumors	Phase 1	Recruiting	None	NCT04045496 NCT04121286
SH3809	SHP2	Advanced solid tumor	Phase1	Recruiting	None	NCT04843033
ERAS-601	SHP2	Advanced or metastatic solid tumors	Phase1	Recruiting	MEK inhibitor	NCT04670679
Sodium stibogluconate	SHP2	Myelodysplastic Syndromes	Phase 1	Terminated	None	NCT01009502
		Advanced Cancer		Completed	Interferon alpha-2b	NCT00629200
		Solid Tumors
MSI-1436C	PTP1B	Metastatic Breast Cancer	Phase1	Terminated	None	NCT02524951
MSI-1436	PTP1B	Diabetes Mellitus	Phase1	Terminated	None	NCT00806338
ISIS-113715	PTP1B	Type 2 Diabetes Mellitus	Phase 2	Terminated	None	NCT00330200
PRL3-zumab	PRL3	Advanced Solid Tumors	Phase1	Recruiting	None	NCT03191682
LB-100	PP2A	Solid tumor	Phase1	Completed	Docetaxel	NCT01837667
		Recurrent Glioblastoma	Phase2	Recruiting	None	NCT03027388